US 12,310,930 B2
Stabilization of epinephrine formulations
Yosyong Surakitbanharn, San Diego, CA (US)
Assigned to YS PHARMTECH, San Diego, CA (US)
Filed by Yosyong Surakitbanharn, San Diego, CA (US)
Filed on Apr. 19, 2023, as Appl. No. 18/136,484.
Application 18/136,484 is a continuation of application No. 17/072,126, filed on Oct. 16, 2020, abandoned.
Application 17/072,126 is a continuation of application No. 16/310,728, abandoned, previously published as PCT/US2017/037917, filed on Jun. 16, 2017.
Claims priority of provisional application 62/476,852, filed on Mar. 26, 2017.
Claims priority of provisional application 62/351,462, filed on Jun. 17, 2016.
Prior Publication US 2023/0355551 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/137 (2006.01); A61K 9/08 (2006.01); A61K 31/095 (2006.01); A61K 47/18 (2017.01); A61K 47/40 (2006.01)
CPC A61K 31/137 (2013.01) [A61K 9/08 (2013.01); A61K 47/183 (2013.01); A61K 47/40 (2013.01); A61K 31/095 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising:
l-epinephrine;
free of an epinephrine degradation product, the epinephrine degradation product being epinephrine sulfonic acid (ESA);
one or more antioxidant, the antioxidant being present in the composition in an amount of about 0.005 wt. % to about 0.03 wt. %, wherein the one or more antioxidant comprises cysteine, thioglycerol, or any combination thereof; and
an aqueous medium;
wherein the pharmaceutical composition has a pH of about 2.5 to about 3.5 and a weight ratio of the antioxidant to l-epinephrine is about 1:10 to about 7:10.